AUS
NZ
UK
CA
USA
IND
Highlights
- Freedom Care Group faces potential license revocation by NDIS.
- Cash flow impact as NDIS program contributes significantly to revenue.
- Review triggered following a payment suspension and ongoing audit.
Freedom Care Group (ASX:FCG) recently announced that the National Disability Insurance Scheme (NDIS) is considering revoking its license as a service provider, which could significantly impact the company’s financial stability. On Wednesday, Freedom Care disclosed that it had received communication from the NDIS Commission stating that a permanent ban on its registration was under consideration. Shares in Freedom Care Group saw a drop of over three percent following this news as investors reacted to the uncertainty around its future involvement with the NDIS.
The company’s financial reliance on the NDIS is significant, as the scheme is a primary source of cash flow for Freedom Care. The potential license revocation could result in Freedom Care's inability to re-register for the scheme in the future, raising concerns about its long-term revenue generation. In response to the NDIS’s communication, Freedom Care has engaged legal representation to address these issues and potentially challenge the decision.
The exact reasons behind the NDIS Commission’s decision to consider revocation remain unclear, but Freedom Care’s announcement on Wednesday pointed to an ongoing suspension of payments as a contributing factor. This suspension relates to a review of Freedom Care's support services claims, which has been prolonged, adding to the company’s operational challenges. The company has been advised that an update on the review is expected within the week.
Another layer of scrutiny came when Freedom Care recently underwent an audit as part of its status as a registered NDIS provider. Non-Executive Chair Zoran Grujic noted that the audit took place in late October, in line with annual requirements for all NDIS-registered providers. This audit process is a regular feature of compliance for service providers within the NDIS, and it reflects the broader cost-cutting review currently led by Bill Shorten, which has placed additional pressures on entities within the welfare program.
A subsidiary within Freedom Care, which handles around 80% of the company’s revenue-generating operations, processes payments and is directly impacted by the current NDIS review. As Freedom Care awaits further updates on the review, the company remains focused on addressing the issues raised and ensuring compliance to secure its position within the NDIS framework.
Freedom Care’s last recorded trading price stood at 12.5 cents per share, highlighting the market’s cautious stance as it monitors the ongoing developments surrounding the NDIS review and its potential consequences for the company.
